Shots:

• The P-II (NCT03209973) study result involves assessing of tislelizumab (200mg- IV- q3w) as a monothx. in 70 patients with R/R to autologous stem cell transplantation (ASCT) or 2L+ r/r cHL
• The P-II study results: high anti-tumor activity in patients; ORR (87.1%); CR (62.9%); PR (24.3%); @12mos. PFS (73.8%); well tolerated; presented at 24thCongress of the European Hematology Association (EHA)
• Tislelizumab (BGB-A317) is an IgG4 anti–PD-1 mAb- minimizing the binding of FcγR on macrophages- being developed by BeiGene and Celgene for solid tumors cancer outside Asia (Ex Japan). NMPA has accepted its NDA and has granted PR designation for r/r cHL in China

Ref: Beigene | Image: Switzerland Global Enterprise